Details of the Drug Combination

General Information of Drug Combination (ID: DCBJA9T)

Drug Combination Name
Imatinib Mitomycin
Indication
Disease Entry Status REF
Colon carcinoma Investigative [1]
Component Drugs Imatinib   DM7RJXL Mitomycin   DMH0ZJE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KM12
Zero Interaction Potency (ZIP) Score: 3.64
Bliss Independence Score: 8.45
Loewe Additivity Score: 3.42
LHighest Single Agent (HSA) Score: 2.76

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Imatinib
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [2]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [3]
Choroidal neovascularization 9B76 Approved [3]
Chronic eosinophilic leukemia N.A. Approved [3]
Chronic myelogenous leukaemia 2A20.0 Approved [4]
Chronic myeloid leukaemia 2A20 Approved [5]
Dermatofibrosarcoma protuberans N.A. Approved [3]
Gastrointestinal stromal tumour 2B5B Approved [3]
Leukemia N.A. Approved [3]
Malignant peripheral nerve sheath tumor N.A. Approved [3]
Myeloproliferative neoplasm 2A20 Approved [3]
Pulmonary hypertension BB01 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Intestinal cancer 2C0Z Phase 3 [4]
Lung cancer 2C25.0 Phase 2 [4]
Idiopathic hypereosinophilic syndrome N.A. Investigative [3]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [7]
Scleroderma 4A42 Investigative [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [7]
Systemic mastocytosis 2A21.0 Investigative [8]
Imatinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mcl-1 messenger RNA (MCL-1 mRNA) TTN6ORK MCL1_HUMAN . [8]
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [15]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [15]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [15]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Imatinib Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [16]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [17]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [18]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [19]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [20]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Imatinib Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [21]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [22]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [23]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [24]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [25]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [26]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [27]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Imatinib Interacts with 95 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Methylation [28]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [28]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Methylation [28]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Methylation [28]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [29]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [29]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Decreases Expression [30]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Expression [30]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Decreases Expression [30]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) OT2NHE5E ODPB_HUMAN Decreases Expression [30]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [30]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [30]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Expression [30]
Eukaryotic translation initiation factor 4B (EIF4B) OTE8TXA8 IF4B_HUMAN Decreases Expression [30]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Expression [30]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [30]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [30]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [30]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [30]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [30]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Expression [30]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [31]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [32]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [33]
Autophagy-related protein 13 (ATG13) OTYMHNEJ ATG13_HUMAN Increases Phosphorylation [12]
Platelet-derived growth factor subunit B (PDGFB) OTMFMFC3 PDGFB_HUMAN Decreases Expression [34]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Expression [35]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [36]
Keratin, type I cytoskeletal 14 (KRT14) OTUVZ1DW K1C14_HUMAN Increases Expression [37]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [38]
Heat shock protein beta-1 (HSPB1) OTHFZ8ED HSPB1_HUMAN Increases Expression [33]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [39]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [33]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [40]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [35]
Cathepsin B (CTSB) OTP9G5QB CATB_HUMAN Increases Expression [12]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Phosphorylation [41]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM) OT1QY9JM PFKAM_HUMAN Decreases Expression [42]
Platelet-derived growth factor receptor beta (PDGFRB) OTYSNK9Q PGFRB_HUMAN Decreases Expression [34]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [43]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [33]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [44]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [38]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [14]
Lysosome-associated membrane glycoprotein 1 (LAMP1) OTYE92QY LAMP1_HUMAN Increases Expression [12]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases Expression [33]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Increases Expression [37]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [45]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [46]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Expression [34]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Increases Expression [33]
Histidine decarboxylase (HDC) OT4WA5YQ DCHS_HUMAN Decreases Expression [47]
Transcription factor EB (TFEB) OTJUJJQY TFEB_HUMAN Affects Localization [12]
Fibroblast growth factor receptor 3 (FGFR3) OTSAXDIL FGFR3_HUMAN Decreases Expression [48]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [33]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [49]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Increases Expression [33]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [35]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [33]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [40]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [40]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Cleavage [36]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [50]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [51]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [52]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [12]
Hexokinase-2 (HK2) OTC0GCQO HXK2_HUMAN Decreases Expression [42]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [12]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Expression [33]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [50]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [44]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [53]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [43]
Forkhead box protein M1 (FOXM1) OT5887KR FOXM1_HUMAN Decreases Expression [50]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [54]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [12]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Increases Expression [12]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [55]
NGFI-A-binding protein 2 (NAB2) OTG4BDF3 NAB2_HUMAN Increases Expression [33]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [56]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [39]
TRAF family member-associated NF-kappa-B activator (TANK) OTZSGFIK TANK_HUMAN Increases Expression [33]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) OTZM6MHU NLRP3_HUMAN Increases Expression [36]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Increases Activity [55]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [57]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [12]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [58]
V-type proton ATPase subunit H (ATP6V1H) OTX17GQ9 VATH_HUMAN Increases Expression [12]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Increases Response To Substance [59]
LYR motif-containing protein 9 (LYRM9) OT1MILTK LYRM9_HUMAN Affects Response To Substance [60]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Increases ADR [61]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [62]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [63]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Decreases Response To Substance [52]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Increases Response To Substance [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 95 DOT(s)
Indication(s) of Mitomycin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [9]
Gastrointestinal cancer 2C11 Approved [9]
Pancreatic adenocarcinoma N.A. Approved [10]
Solid tumour/cancer 2A00-2F9Z Approved [11]
Urinary bladder cancer N.A. Approved [10]
Urinary bladder neoplasm N.A. Approved [10]
Urinary system neoplasm N.A. Approved [10]
Urinary tract disease GC2Z Approved [10]
Bladder disease DC11-DC1Z Investigative [10]
Colon cancer 2B90.Z Investigative [10]
Mitomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Binder [70]
------------------------------------------------------------------------------------
Mitomycin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [71]
------------------------------------------------------------------------------------
Mitomycin Interacts with 274 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [72]
Alternative prion protein (PRNP) OTE85L1Q APRIO_HUMAN Increases Expression [73]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [73]
HLA class I histocompatibility antigen, C alpha chain (HLA-C) OTV38BUJ HLAC_HUMAN Decreases Expression [73]
Bone morphogenetic protein 4 (BMP4) OTPZMDFH BMP4_HUMAN Decreases Expression [73]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [73]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [73]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [73]
DNA ligase 1 (LIG1) OTEEQS43 DNLI1_HUMAN Decreases Expression [73]
Nuclear transcription factor Y subunit alpha (NFYA) OTWFFOVH NFYA_HUMAN Increases Expression [73]
Ephrin type-A receptor 2 (EPHA2) OTI6QNX2 EPHA2_HUMAN Decreases Expression [73]
Replication factor C subunit 4 (RFC4) OTWALD2R RFC4_HUMAN Decreases Expression [73]
Matrix metalloproteinase-14 (MMP14) OT9C197Z MMP14_HUMAN Decreases Expression [73]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1) OTK71JYU TCP4_HUMAN Increases Expression [73]
Small ribosomal subunit protein eS1 (RPS3A) OTUEP7CL RS3A_HUMAN Increases Expression [73]
Microtubule-associated protein RP/EB family member 1 (MAPRE1) OTCVQD60 MARE1_HUMAN Increases Expression [73]
Histone-binding protein RBBP7 (RBBP7) OTLB56HX RBBP7_HUMAN Increases Expression [73]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [74]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Increases Expression [75]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [75]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [75]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Increases Expression [75]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Increases Expression [75]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [75]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [75]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [75]
DNA damage-binding protein 2 (DDB2) OTO8HVVB DDB2_HUMAN Increases Expression [75]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [76]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1) OTDG5VW7 SDHF1_HUMAN Decreases Expression [65]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [65]
E3 ubiquitin-protein ligase TRIM38 (TRIM38) OT6SP1M9 TRI38_HUMAN Decreases Expression [65]
Torsin-1A (TOR1A) OTYCLGJU TOR1A_HUMAN Decreases Expression [65]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [77]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Increases Phosphorylation [78]
Transcription factor EC (TFEC) OTUST8MR TFEC_HUMAN Decreases Expression [65]
Regulator of G-protein signaling 16 (RGS16) OTBKZASI RGS16_HUMAN Decreases Expression [65]
E3 ubiquitin-protein ligase RNF113A (RNF113A) OTR6N7HU R113A_HUMAN Decreases Expression [65]
HMG box-containing protein 1 (HBP1) OTDPGGDV HBP1_HUMAN Decreases Expression [65]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [65]
Myelin protein zero-like protein 1 (MPZL1) OTJSUUHR MPZL1_HUMAN Decreases Expression [65]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Phosphorylation [78]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [79]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [80]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Increases Mutagenesis [81]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [80]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [80]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [82]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [79]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Activity [83]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [84]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [85]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [84]
CD59 glycoprotein (CD59) OTSUMQDH CD59_HUMAN Increases Mutagenesis [86]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [87]
Beta-galactosidase (GLB1) OTB0TKAG BGAL_HUMAN Increases Activity [80]
rRNA 2'-O-methyltransferase fibrillarin (FBL) OTRODIE5 FBRL_HUMAN Affects Localization [88]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [65]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [89]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [90]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [90]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Decreases Expression [65]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [91]
Replication factor C subunit 1 (RFC1) OT3L5PK3 RFC1_HUMAN Decreases Expression [65]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [92]
RNA-binding protein 34 (RBM34) OTX3LUGI RBM34_HUMAN Decreases Expression [65]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [89]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [80]
LIM/homeobox protein Lhx2 (LHX2) OTK61NP8 LHX2_HUMAN Decreases Expression [65]
DNA mismatch repair protein Msh6 (MSH6) OT46FP09 MSH6_HUMAN Decreases Expression [65]
RecQ-like DNA helicase BLM (BLM) OTEJOAJX BLM_HUMAN Decreases Expression [65]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [65]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [91]
Ras-related protein Rap-2b (RAP2B) OTD2NDQP RAP2B_HUMAN Decreases Expression [65]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Secretion [92]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [93]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [65]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [94]
Protein kinase C zeta type (PRKCZ) OTN2FE42 KPCZ_HUMAN Increases Cleavage [92]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Increases Expression [90]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Decreases Expression [85]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [95]
Tripartite motif-containing protein 26 (TRIM26) OTS0DJIP TRI26_HUMAN Decreases Expression [65]
E3 ubiquitin-protein ligase TRIM32 (TRIM32) OTJOV0PG TRI32_HUMAN Decreases Expression [65]
Chromatin assembly factor 1 subunit A (CHAF1A) OTXSSY4H CAF1A_HUMAN Decreases Expression [65]
Chromatin assembly factor 1 subunit B (CHAF1B) OTOMK4KH CAF1B_HUMAN Decreases Expression [65]
Interleukin-18 (IL18) OTBB2A8O IL18_HUMAN Decreases Expression [94]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Decreases Expression [65]
Histone RNA hairpin-binding protein (SLBP) OTVYYQRT SLBP_HUMAN Decreases Expression [65]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [92]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Expression [95]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Decreases Expression [65]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [65]
Partner and localizer of BRCA2 (PALB2) OT6DNDBG PALB2_HUMAN Decreases Expression [65]
Leucine-rich repeat-containing protein 47 (LRRC47) OTSE8NAO LRC47_HUMAN Decreases Expression [65]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [91]
Cytochrome c oxidase assembly factor 7 (COA7) OTRQJYL6 COA7_HUMAN Decreases Expression [65]
Mitochondrial potassium channel (CCDC51) OTOJNHNA MITOK_HUMAN Decreases Expression [65]
Integrator complex subunit 15 (INTS15) OT3O4INM INT15_HUMAN Decreases Expression [65]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Decreases Expression [65]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [65]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [65]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [65]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Decreases Expression [65]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [65]
Fanconi anemia group D2 protein (FANCD2) OTVEB5LF FACD2_HUMAN Increases Ubiquitination [78]
tRNA pseudouridine(38/39) synthase (PUS3) OT6WG6M2 PUS3_HUMAN Decreases Expression [65]
Transmembrane protein 185B (TMEM185B) OTGNYS0J T185B_HUMAN Decreases Expression [65]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [65]
GrpE protein homolog 1, mitochondrial (GRPEL1) OT8O00YJ GRPE1_HUMAN Decreases Expression [65]
Forkhead box protein J2 (FOXJ2) OTPT639J FOXJ2_HUMAN Decreases Expression [65]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Decreases Expression [65]
rRNA methyltransferase 2, mitochondrial (MRM2) OTRYA1HU MRM2_HUMAN Decreases Expression [65]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Expression [65]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Affects Response To Substance [68]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [68]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Affects Response To Substance [68]
Fanconi-associated nuclease 1 (FAN1) OT1LM1HZ FAN1_HUMAN Increases Response To Substance [96]
Replication factor C subunit 3 (RFC3) OT1MS7AO RFC3_HUMAN Affects Response To Substance [68]
CD9 antigen (CD9) OT2184XU CD9_HUMAN Affects Response To Substance [68]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1) OT2E7A6W KANK1_HUMAN Affects Response To Substance [68]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [68]
Mitochondrial fission 1 protein (FIS1) OT2HL10J FIS1_HUMAN Affects Response To Substance [68]
Cytoplasmic aconitate hydratase (ACO1) OT2VUR7L ACOHC_HUMAN Affects Response To Substance [68]
Syncytin-2 (ERVFRD-1) OT3064D7 SYCY2_HUMAN Affects Response To Substance [68]
Protein FAM171A1 (FAM171A1) OT33BHEP F1711_HUMAN Affects Response To Substance [68]
Sister chromatid cohesion protein PDS5 homolog A (PDS5A) OT34P56Z PDS5A_HUMAN Affects Response To Substance [68]
Excitatory amino acid transporter 3 (SLC1A1) OT3B9M6W EAA3_HUMAN Affects Response To Substance [68]
Syntabulin (SYBU) OT3FQV7N SYBU_HUMAN Affects Response To Substance [68]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [68]
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Affects Response To Substance [68]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Response To Substance [97]
Pyridoxal kinase (PDXK) OT40AJ5J PDXK_HUMAN Affects Response To Substance [68]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Affects Response To Substance [68]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Affects Response To Substance [68]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Increases Response To Substance [98]
Neprilysin (MME) OT5Q39P8 NEP_HUMAN Affects Response To Substance [68]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Affects Response To Substance [68]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2) OT6MFOWF TGM2_HUMAN Affects Response To Substance [68]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [68]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Affects Response To Substance [68]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Increases Response To Substance [99]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [68]
Transcriptional regulator ATRX (ATRX) OT77RSQW ATRX_HUMAN Affects Response To Substance [68]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Affects Response To Substance [68]
Ras-related protein Rab-17 (RAB17) OT7NBUGQ RAB17_HUMAN Affects Response To Substance [68]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Affects Response To Substance [68]
Pirin (PIR) OT8ALXHU PIR_HUMAN Affects Response To Substance [68]
Myelin proteolipid protein (PLP1) OT8CM9CX MYPR_HUMAN Affects Response To Substance [68]
Protein-S-isoprenylcysteine O-methyltransferase (ICMT) OT8CNKBO ICMT_HUMAN Affects Response To Substance [68]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Affects Response To Substance [68]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E) OT8GPFT5 2A5E_HUMAN Decreases Response To Substance [100]
cAMP-dependent protein kinase inhibitor alpha (PKIA) OT8M5GVO IPKA_HUMAN Affects Response To Substance [68]
Melanoma-associated antigen 12 (MAGEA12) OT8ULELL MAGAC_HUMAN Affects Response To Substance [68]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A) OT9297OG 2ABA_HUMAN Decreases Response To Substance [100]
Tissue factor pathway inhibitor (TFPI) OTA0FX16 TFPI1_HUMAN Affects Response To Substance [68]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2) OTAKUO27 ACOT2_HUMAN Affects Response To Substance [68]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [101]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Affects Response To Substance [68]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Affects Response To Substance [68]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [68]
ETS domain-containing protein Elk-3 (ELK3) OTBM9BHT ELK3_HUMAN Affects Response To Substance [68]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Affects Response To Substance [68]
Protein PRRC2C (PRRC2C) OTBX3MXM PRC2C_HUMAN Affects Response To Substance [68]
Melanocyte protein PMEL (PMEL) OTCDDHHM PMEL_HUMAN Affects Response To Substance [68]
BMP and activin membrane-bound inhibitor homolog (BAMBI) OTCEJ8W5 BAMBI_HUMAN Affects Response To Substance [68]
Creatine kinase U-type, mitochondrial (CKMT1A) OTCINHH5 KCRU_HUMAN Affects Response To Substance [68]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) OTCJ458Q AT1A1_HUMAN Affects Response To Substance [68]
CD166 antigen (ALCAM) OTCO4LP7 CD166_HUMAN Affects Response To Substance [68]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [68]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Response To Substance [102]
Collagen alpha-3(IX) chain (COL9A3) OTCUJOEK CO9A3_HUMAN Affects Response To Substance [68]
A-kinase anchor protein 12 (AKAP12) OTCVRDDX AKA12_HUMAN Affects Response To Substance [68]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Affects Response To Substance [68]
Dickkopf-related protein 3 (DKK3) OTDU94EY DKK3_HUMAN Affects Response To Substance [68]
dTDP-D-glucose 4,6-dehydratase (TGDS) OTEOFLOS TGDS_HUMAN Affects Response To Substance [68]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Affects Response To Substance [68]
Ras association domain-containing protein 1 (RASSF1) OTEZIPB7 RASF1_HUMAN Increases Response To Substance [103]
Protocadherin Fat 1 (FAT1) OTF174DH FAT1_HUMAN Affects Response To Substance [68]
Midkine (MDK) OTF24HKC MK_HUMAN Affects Response To Substance [68]
Serine/arginine-rich splicing factor 1 (SRSF1) OTF61HOV SRSF1_HUMAN Affects Response To Substance [68]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C) OTF7CGO2 2A5G_HUMAN Increases Response To Substance [100]
G antigen 7 (GAGE7) OTF8BTR9 GAGE7_HUMAN Affects Response To Substance [68]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [68]
Catenin alpha-1 (CTNNA1) OTFC725Z CTNA1_HUMAN Affects Response To Substance [68]
Sortilin (SORT1) OTFCQ4B1 SORT_HUMAN Affects Response To Substance [68]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Affects Response To Substance [68]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Affects Response To Substance [68]
Tudor domain-containing protein 3 (TDRD3) OTG83E2C TDRD3_HUMAN Affects Response To Substance [68]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Affects Response To Substance [68]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [68]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [104]
Sigma intracellular receptor 2 (TMEM97) OTH76ZWK SGMR2_HUMAN Affects Response To Substance [68]
Transmembrane protein 156 (TMEM156) OTH7YJID TM156_HUMAN Affects Response To Substance [68]
Probable JmjC domain-containing histone demethylation protein 2C (JMJD1C) OTHAWK8C JHD2C_HUMAN Affects Response To Substance [68]
Unconventional myosin-X (MYO10) OTHB78ZQ MYO10_HUMAN Affects Response To Substance [68]
Tribbles homolog 2 (TRIB2) OTHSX3MX TRIB2_HUMAN Affects Response To Substance [68]
Actin-binding LIM protein 1 (ABLIM1) OTHXEK3E ABLM1_HUMAN Affects Response To Substance [68]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [68]
Protein S100-A11 (S100A11) OTI57KDN S10AB_HUMAN Affects Response To Substance [68]
Protein S100-A10 (S100A10) OTI71243 S10AA_HUMAN Affects Response To Substance [68]
Melanoma-associated antigen 6 (MAGEA6) OTI8S0O2 MAGA6_HUMAN Affects Response To Substance [68]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Increases Response To Substance [105]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Response To Substance [68]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Affects Response To Substance [68]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Affects Response To Substance [68]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Affects Response To Substance [68]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Affects Response To Substance [68]
Hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1) OTJQL0I3 HEY1_HUMAN Affects Response To Substance [68]
E3 ubiquitin-protein ligase MYLIP (MYLIP) OTL0PFGV MYLIP_HUMAN Affects Response To Substance [68]
Hematopoietically-expressed homeobox protein HHEX (HHEX) OTLIUVYX HHEX_HUMAN Affects Response To Substance [68]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2) OTLNA39Z NMT2_HUMAN Affects Response To Substance [68]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [106]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Affects Response To Substance [68]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Response To Substance [68]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Affects Response To Substance [68]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Affects Response To Substance [68]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Affects Response To Substance [68]
Cysteine-rich hydrophobic domain-containing protein 2 (CHIC2) OTNE3T6Z CHIC2_HUMAN Affects Response To Substance [68]
Inositol monophosphatase 2 (IMPA2) OTNFB9YN IMPA2_HUMAN Affects Response To Substance [68]
Neural cell adhesion molecule L1 (L1CAM) OTNWAQ4Y L1CAM_HUMAN Affects Response To Substance [68]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Affects Response To Substance [107]
Kynurenine--oxoglutarate transaminase 3 (KYAT3) OTO4U2QK KAT3_HUMAN Affects Response To Substance [68]
Beta-secretase 2 (BACE2) OTO5YQVK BACE2_HUMAN Affects Response To Substance [68]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Affects Response To Substance [68]
SH3 domain-binding protein 5 (SH3BP5) OTOOEGUJ 3BP5_HUMAN Affects Response To Substance [68]
Glutathione S-transferase Mu 4 (GSTM4) OTOTF8DU GSTM4_HUMAN Affects Response To Substance [68]
Ras-related protein Rab-20 (RAB20) OTP9OOVS RAB20_HUMAN Affects Response To Substance [68]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Affects Response To Substance [68]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [68]
Kazrin (KAZN) OTPM7BYM KAZRN_HUMAN Affects Response To Substance [68]
DNA-binding protein inhibitor ID-4 (ID4) OTPMJ39I ID4_HUMAN Affects Response To Substance [68]
Centrosomal protein of 57 kDa (CEP57) OTPOHLIX CEP57_HUMAN Affects Response To Substance [68]
Epithelial membrane protein 2 (EMP2) OTPS2H0L EMP2_HUMAN Affects Response To Substance [68]
Dermatan-sulfate epimerase (DSE) OTQ108VJ DSE_HUMAN Affects Response To Substance [68]
Adhesion G-protein coupled receptor G1 (ADGRG1) OTQBB8NT AGRG1_HUMAN Affects Response To Substance [68]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A) OTQDYH8E ASM3A_HUMAN Affects Response To Substance [68]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [68]
High mobility group protein HMG-I/HMG-Y (HMGA1) OTQUSHPX HMGA1_HUMAN Affects Response To Substance [68]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Affects Response To Substance [68]
Dr1-associated corepressor (DRAP1) OTRWLF6D NC2A_HUMAN Affects Response To Substance [68]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [68]
Terminal nucleotidyltransferase 5A (TENT5A) OTSYF511 TET5A_HUMAN Affects Response To Substance [68]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Affects Response To Substance [68]
DNA repair protein RAD51 homolog 3 (RAD51C) OTUD6SY5 RA51C_HUMAN Increases Response To Substance [108]
Calcium-dependent secretion activator 2 (CADPS2) OTV1FW0M CAPS2_HUMAN Affects Response To Substance [68]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Affects Response To Substance [68]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [106]
Ensconsin (MAP7) OTVSSJ33 MAP7_HUMAN Affects Response To Substance [68]
Protein artemis (DCLRE1C) OTW3KB1I DCR1C_HUMAN Decreases Response To Substance [69]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Affects Response To Substance [68]
Protein mago nashi homolog (MAGOH) OTWRYTOX MGN_HUMAN Affects Response To Substance [68]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Affects Response To Substance [68]
Acylamino-acid-releasing enzyme (APEH) OTX258QE ACPH_HUMAN Affects Response To Substance [68]
Hematopoietic lineage cell-specific protein (HCLS1) OTX7WGYN HCLS1_HUMAN Affects Response To Substance [68]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Response To Substance [68]
Long-chain fatty acid transport protein 3 (SLC27A3) OTXB60L7 S27A3_HUMAN Affects Response To Substance [68]
Metallothionein-1E (MT1E) OTXJKU4Y MT1E_HUMAN Affects Response To Substance [68]
Arginine vasopressin-induced protein 1 (AVPI1) OTXSBR60 AVPI1_HUMAN Affects Response To Substance [68]
Neuroendocrine protein 7B2 (SCG5) OTXSJMT1 7B2_HUMAN Affects Response To Substance [68]
Carbamoyl-phosphate synthase , mitochondrial (CPS1) OTXV8NSR CPSM_HUMAN Affects Response To Substance [68]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Affects Response To Substance [68]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Affects Response To Substance [68]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B) OTY94WRA HM20B_HUMAN Affects Response To Substance [68]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Affects Response To Substance [68]
LIM and calponin homology domains-containing protein 1 (LIMCH1) OTYPC4XA LIMC1_HUMAN Affects Response To Substance [68]
Galectin-3 (LGALS3) OTYQT0ZI LEG3_HUMAN Affects Response To Substance [68]
L-dopachrome tautomerase (DCT) OTYVNTBG TYRP2_HUMAN Affects Response To Substance [68]
Epithelial discoidin domain-containing receptor 1 (DDR1) OTYW1SH8 DDR1_HUMAN Affects Response To Substance [68]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [68]
Suppressor of tumorigenicity 7 protein (ST7) OTZG8RC6 ST7_HUMAN Affects Response To Substance [68]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Response To Substance [106]
CTD small phosphatase-like protein (CTDSPL) OTZJ0CZK CTDSL_HUMAN Affects Response To Substance [68]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [68]
Eukaryotic translation initiation factor 5B (EIF5B) OTZTT22W IF2P_HUMAN Affects Response To Substance [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 274 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Large cell lung carcinoma DC266VA NCI-H460 Investigative [109]
Lung adenocarcinoma DCF0GDQ EKVX Investigative [109]
Lung adenocarcinoma DC556D3 NCI-H522 Investigative [109]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Imatinib FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
6 ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
7 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
8 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
10 Mitomycin FDA Label
11 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
12 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
13 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778.
14 Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004 Sep 1;101(5):979-88. doi: 10.1002/cncr.20457.
15 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
16 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
17 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
18 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
19 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
20 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
25 Drug Interactions Flockhart Table
26 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
27 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
28 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
29 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
30 A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
31 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
32 Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-B inactivation. Toxicol In Vitro. 2012 Apr;26(3):396-405.
33 Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6(9):e24831. doi: 10.1371/journal.pone.0024831. Epub 2011 Sep 14.
34 Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer. 2005 May 1;103(9):1800-9. doi: 10.1002/cncr.20973.
35 Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?. Clin Exp Immunol. 2008 Mar;151(3):391-8. doi: 10.1111/j.1365-2249.2007.03572.x. Epub 2008 Jan 10.
36 Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
37 Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004 Jul;15(4):253-5. doi: 10.1080/09546630410015556.
38 AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci. 2021 Jan;112(1):194-204. doi: 10.1111/cas.14698. Epub 2020 Nov 16.
39 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
40 Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
41 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005 Feb 1;11(3):1336-41.
42 Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
43 Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
44 Saikosaponin D disrupts platelet-derived growth factor- receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem Biol Interact. 2013 Oct 25;206(1):76-82. doi: 10.1016/j.cbi.2013.08.006. Epub 2013 Aug 28.
45 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
46 Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.
47 The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood. 2006 Nov 15;108(10):3538-47. doi: 10.1182/blood-2005-12-028456. Epub 2006 Jul 18.
48 Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003 Dec;17(12):2418-25. doi: 10.1038/sj.leu.2403152.
49 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
50 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
51 In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002 Jul;30(7):729-37. doi: 10.1016/s0301-472x(02)00836-6.
52 Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007 May;78(5):417-31. doi: 10.1111/j.1600-0609.2007.00835.x.
53 The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
54 Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022 Jul 15;365:11-23. doi: 10.1016/j.toxlet.2022.06.001. Epub 2022 Jun 6.
55 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
56 A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. Toxicol Lett. 2022 Jun 15;363:11-26. doi: 10.1016/j.toxlet.2022.05.002. Epub 2022 May 18.
57 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
58 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
59 Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004 Jul;50(7):1205-13. doi: 10.1373/clinchem.2004.031112. Epub 2004 Apr 23.
60 Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci. 2016 May;151(1):10-22. doi: 10.1093/toxsci/kfw032. Epub 2016 Mar 22.
61 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
62 Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
63 Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.
64 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
65 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
66 TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death. Life Sci. 2006 Feb 23;78(13):1499-507. doi: 10.1016/j.lfs.2005.07.021. Epub 2005 Oct 14.
67 Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):285-7. doi: 10.1007/s11596-007-0317-5.
68 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
69 Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells. J Radiat Res. 2011;52(4):415-24. doi: 10.1269/jrr.10168.
70 Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
71 In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
72 Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):297-304. doi: 10.1007/s00417-007-0695-1. Epub 2007 Oct 13.
73 Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
74 Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
75 Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
76 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
77 Trace levels of mitomycin C disrupt genomic integrity and lead to DNA damage response defect in long-term-cultured human embryonic stem cells. Arch Toxicol. 2015 Jan;89(1):33-45. doi: 10.1007/s00204-014-1250-6. Epub 2014 May 18.
78 Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. Oncotarget. 2015 Sep 22;6(28):25770-83. doi: 10.18632/oncotarget.4514.
79 Effects of mitomycin-C on normal dermal fibroblasts. Laryngoscope. 2006 Apr;116(4):514-7. doi: 10.1097/01.MLG.0000205590.62824.0A.
80 Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3 signaling. Toxicol Lett. 2021 Nov 1;352:61-69. doi: 10.1016/j.toxlet.2021.09.015. Epub 2021 Oct 5.
81 DNA polymerase kappa protects human cells against MMC-induced genotoxicity through error-free translesion DNA synthesis. Genes Environ. 2017 Jan 7;39:6. doi: 10.1186/s41021-016-0067-3. eCollection 2017.
82 In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res. 2005;115(3):219-28. doi: 10.1016/j.thromres.2004.09.001.
83 Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
84 Dexamethasone reduces mitomycin C-related inflammatory cytokine expression without inducing further cell death in corneal fibroblasts. Wound Repair Regen. 2010 Jan-Feb;18(1):59-69. doi: 10.1111/j.1524-475X.2009.00551.x. Epub 2009 Dec 11.
85 The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep. 2010 Jul;37(6):2693-701. doi: 10.1007/s11033-009-9801-2. Epub 2009 Sep 13.
86 Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
87 Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
88 Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
89 Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
90 Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.
91 Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3545-52. doi: 10.1167/iovs.04-1358.
92 Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett. 2000 Oct 1;158(2):125-32. doi: 10.1016/s0304-3835(00)00489-4.
93 Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol Sci. 2008 Apr;102(2):232-40. doi: 10.1093/toxsci/kfm305. Epub 2007 Dec 20.
94 Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells. Cancer Lett. 2006 Jun 8;237(1):33-44. doi: 10.1016/j.canlet.2005.05.043. Epub 2005 Jul 12.
95 Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas. Mol Vis. 2008 Jun 30;14:1222-8.
96 FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012 Jul 8;44(8):910-5. doi: 10.1038/ng.2347.
97 O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol. 2006 Mar 1;211(2):97-105. doi: 10.1016/j.taap.2005.06.009. Epub 2005 Jul 22.
98 Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget. 2015 Sep 29;6(29):27674-87. doi: 10.18632/oncotarget.4876.
99 MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest. 1997 Dec 1;100(11):2873-80. doi: 10.1172/JCI119836.
100 PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
101 Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
102 Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
103 Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721. J Gastroenterol Hepatol. 2007 May;22(5):683-9. doi: 10.1111/j.1440-1746.2006.04676.x.
104 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
105 Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
106 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
107 [Effect of adenovirus-mediated mutant exogenous P27kip1 gene expression on the chemosensitivities of cholangiocarcinoma cell line]. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1349-52.
108 Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
109 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.